Clinical Trials Logo

Filter by:
NCT ID: NCT01864278 Completed - Clinical trials for Peripheral Artery Disease

Lutonix Global SFA Registry

Start date: December 2012
Phase: N/A
Study type: Observational [Patient Registry]

The registry will enroll patients with claudication or ischemic rest pain and an angiographically significant lesion in the superficial femoral or popliteal artery. Subjects will be treated with the LUTONIX Drug Coated PTA Dilatation Catheter carrying the CE Mark per current Instructions for Use(IFU) and followed clinically for a minimum of 2 years.

NCT ID: NCT01864252 Completed - Clinical trials for Myocardial Reperfusion Injury

Investigation Into the Role of GTN & RIPC in Cardiac Surgery

ERIC-GTN
Start date: January 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether Glyceryl Trinitrate (GTN) reduces injury to the heart during heart-lung bypass surgery in combination with the newer technique of remote ischaemic preconditioning (RIPC).

NCT ID: NCT01864239 Completed - Type 2 Diabetes Clinical Trials

The Medicines Advice Service Evaluation

Start date: November 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to find out whether talking to a pharmacist on the telephone can help to support people taking medicine for a long-term condition.

NCT ID: NCT01864174 Completed - Clinical trials for Type 2 Diabetes Mellitus

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Start date: June 20, 2013
Phase: Phase 4
Study type: Interventional

The purpose of this study is determine if Metformin XR monotherapy in subjects with type 2 diabetes is non-inferior to Metformin IR monotherapy

NCT ID: NCT01864148 Completed - Multiple Sclerosis Clinical Trials

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

SYNERGY
Start date: August 2013
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to evaluate the efficacy of BIIB033 in participants with active relapsing MS when used concurrently with Avonex. Secondary objectives of this study in this study population are to assess the safety, tolerability, and population PK of BIIB033 when used concurrently with Avonex

NCT ID: NCT01863758 Completed - Clinical trials for Severe Haemophilia A

Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A

Start date: August 2013
Phase: Phase 3
Study type: Interventional

To compare the number of breakthrough bleeds under tailored prophylaxis with Human cell line recombinant factor FVIII (Human-cl rhFVIII) with the historical bleeding rate from patients who received Human-cl rhFVIII as on demand treatment.

NCT ID: NCT01863732 Completed - Clinical trials for Spondylitis, Ankylosing

Extension in AS: Sustainability of Benefits, Safety and Tolerability

MEASURE 1 ext
Start date: November 6, 2013
Phase: Phase 3
Study type: Interventional

This 3-year extension study aims at making available the treatment with secukinumab in prefilled syringes (PFS) to patients with ankylosing spondylitis who took part in phase III study CAIN457F2305, defined as "core study", as well as to generate additional data on the sustainability of clinical benefits, safety and tolerability during long-term administration of secukinumab.

NCT ID: NCT01863693 Completed - Ovarian Cancer Clinical Trials

An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1)

Start date: May 10, 2013
Phase:
Study type: Observational

This multicenter, prospective, observational study will evaluate the safety and efficacy of Avastin (bevacizumab) in combination with chemotherapy as first-line treatment in patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in routine clinical practice. Eligible patients will be followed for approximately 15 months.

NCT ID: NCT01863433 Completed - Influenza, Human Clinical Trials

A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers

Start date: May 2013
Phase: Phase 4
Study type: Interventional

This is a study to assess the immune (antibody) response and safety of a bioCSL split virion, inactivated influenza vaccine containing the 2013/2014 formulation of Enzira® vaccine in healthy adult volunteers aged between 18 and 60 years.

NCT ID: NCT01863069 Completed - Clinical trials for Multiple Sclerosis (MS)

Avonex®: Safety, Blood Levels and Effects

C-851
Start date: January 2001
Phase: Phase 1
Study type: Interventional

The primary objective was to determine the tolerability of a new inhaled formulation of interferon beta-1a when given as a single dose, when given once per week for 4 weeks, and compared with standard intramuscular (IM) AVONEX® when given as a single dose. The additional objectives were: To determine the pharmacokinetic (PK) properties of a new inhaled formulation of interferon beta-1a, using an anti-viral cytopathic effect (CPE) assay for human interferon-beta, when given as a single dose, when given once per week for 4 weeks, and compared with standard IM AVONEX® when given as a single dose. To determine the pharmacodynamic (PD) properties of a new inhaled formulation of interferon beta-1a, as measured by serum neopterin and 2-microglobulin, when given as a single dose, when given once per week for 4 weeks, and compared with standard IM AVONEX® when given as a single dose.